ArticleO&G open2026
Cervical Cancer Screening Preferences in Transgender, Nonbinary, and Gender-diverse Patients.
Article in O&G open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe the cervical cancer screening preferences of transgender and gender-diverse individuals presenting for care at the study institution.
methodsWe administered a cross-sectional survey to a convenience sample of 50 patients 18-65 years of age assigned female at birth and self-identifying as transgender or gender-diverse (TGD) from a single academic endocrinology clinic. The 30-item survey, adapted from previous research in this population, included gender-neutral language and various multimedia. We used descriptive statistics to characterize preferences for cervical cancer screening in the form of a ranked list, as well as responses regarding comfort with self-swabs and past experiences with screening. We also performed a post hoc content analysis of free-text responses related to respondent cervical cancer screening preferences.
resultsWe enrolled 51 patients, and 50 completed the survey (98% response rate). Overall, 56.0% of respondents chose human papillomavirus (HPV) self-swab as their first-choice cervical cancer screening preference, followed by provider-collected HPV swab (18.0%), decline screening (14.0%), and Pap test (12.0%). Themes identified from free-text responses around cervical cancer screening included fear of provoking gender dysphoria, value of preventive health care, appreciation of privacy with self-swabs, and desire for gender-diverse-competent health care teams.
conclusionIn this sample of TGD patients, the majority of respondents preferred self-collected HPV tests for cervical cancer screening, and some respondents preferred to forego screening altogether. Participants emphasized the importance of preventive health care and clinician competency in transgender health and trauma-informed care.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.